These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23544761)

  • 1. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants.
    Herman WH; Edelstein SL; Ratner RE; Montez MG; Ackermann RT; Orchard TJ; Foulkes MA; Zhang P; Saudek CD; Brown MB;
    Am J Manag Care; 2013; 19(3):194-202. PubMed ID: 23544761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2012 Apr; 35(4):723-30. PubMed ID: 22442395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH; Hoerger TJ; Brandle M; Hicks K; Sorensen S; Zhang P; Hamman RF; Ackermann RT; Engelgau MM; Ratner RE;
    Ann Intern Med; 2005 Mar; 142(5):323-32. PubMed ID: 15738451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
    Diabetes Prevention Program Research Group
    Diabetes Care; 2003 Sep; 26(9):2518-23. PubMed ID: 12941712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of diabetes prevention: results from the Diabetes Prevention Program and the Diabetes Prevention Program Outcomes Study.
    Herman WH
    Clin Diabetes Endocrinol; 2015; 1():9. PubMed ID: 28702228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing cost to prevent diabetes: A retrospective analysis of the Diabetes Prevention Program.
    Carris NW; Cheng F; Kelly WN
    J Am Pharm Assoc (2003); 2017; 57(6):717-722. PubMed ID: 28807660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Eddy DM; Schlessinger L; Kahn R
    Ann Intern Med; 2005 Aug; 143(4):251-64. PubMed ID: 16103469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore.
    Png ME; Yoong JS
    PLoS One; 2014; 9(9):e107225. PubMed ID: 25203633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India.
    Islek D; Weber MB; Ranjit Mohan A; Mohan V; Staimez LR; Harish R; Narayan KMV; Laxy M; Ali MK
    JAMA Netw Open; 2020 Jul; 3(7):e207539. PubMed ID: 32725244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.
    Hernan WH; Brandle M; Zhang P; Williamson DF; Matulik MJ; Ratner RE; Lachin JM; Engelgau MM;
    Diabetes Care; 2003 Jan; 26(1):36-47. PubMed ID: 12502656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
    Herman WH; Pan Q; Edelstein SL; Mather KJ; Perreault L; Barrett-Connor E; Dabelea DM; Horton E; Kahn SE; Knowler WC; Lorenzo C; Pi-Sunyer X; Venditti E; Ye W;
    Diabetes Care; 2017 Dec; 40(12):1668-1677. PubMed ID: 29021207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
    Diabetes Prevention Program Research Group
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
    ; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
    Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.
    Aroda VR; Knowler WC; Crandall JP; Perreault L; Edelstein SL; Jeffries SL; Molitch ME; Pi-Sunyer X; Darwin C; Heckman-Stoddard BM; Temprosa M; Kahn SE; Nathan DM;
    Diabetologia; 2017 Sep; 60(9):1601-1611. PubMed ID: 28770322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program.
    Walker EA; Molitch M; Kramer MK; Kahn S; Ma Y; Edelstein S; Smith K; Johnson MK; Kitabchi A; Crandall J
    Diabetes Care; 2006 Sep; 29(9):1997-2002. PubMed ID: 16936143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Diabetes Prevention Interventions Targeting High-risk Individuals and Whole Populations: A Systematic Review.
    Zhou X; Siegel KR; Ng BP; Jawanda S; Proia KK; Zhang X; Albright AL; Zhang P
    Diabetes Care; 2020 Jul; 43(7):1593-1616. PubMed ID: 33534726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin, Lifestyle Intervention, and Cognition in the Diabetes Prevention Program Outcomes Study.
    Luchsinger JA; Ma Y; Christophi CA; Florez H; Golden SH; Hazuda H; Crandall J; Venditti E; Watson K; Jeffries S; Manly JJ; Pi-Sunyer FX;
    Diabetes Care; 2017 Jul; 40(7):958-965. PubMed ID: 28500216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of metformin in the US diabetes prevention program trial: Simple interpretations need not apply.
    Rittenhouse BE; Alolayan S; Eguale T; Segal AR; Doucette J
    Prev Med; 2024 Jan; 178():107819. PubMed ID: 38092328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.